OncoFlow
DICOM-based workflow management system that integrates entire radiation therapy workflow into one seamless platform
Platform · On PremiseCompany source
Company profile
About OncoSoft. Co.
OncoSoft is a medical AI company specializing in radiation therapy solutions that deliver precision and efficiency through AI-driven technology. The company provides an end-to-end AI software ecosystem for radiation oncology, bridging every step of the clinical workflow from imaging to treatment delivery. Their flagship product, OncoStudio, is an AI-powered auto-contouring software that transforms hours of manual organ segmentation into minutes with clinical-grade precision. The platform has processed over 10 million contours for more than 213,000 patients across multiple clinical sites. OncoFlow, their workflow management system, integrates the entire radiation therapy workflow into one seamless DICOM-based platform, featuring automated plan verification, multi-system data validation, and continuous quality monitoring. The company also has products in development including OncoPlan for particle therapy treatment planning and OncoRPT for radiopharmaceutical therapy workflow management. OncoSoft serves major health systems including Samsung Seoul Hospital, Seoul National University Hospital, Kangbuk Samsung Hospital, and Yonsei Cancer Hospital in South Korea, with recent expansion into the U.S. and Japan markets. The company emphasizes data-centric workflows, global standards compliance (DICOM, HL7 FHIR), and collaboration with clinical experts to continuously improve their products.
Company description OncoSoft. Co. official website
Primary marketSurgical AI & Robotics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at OncoSoft. Co.?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Abdominal cancers
- Breast cancer
- Head and neck cancer
- Pelvic cancers
- Prostate cancer
- Thoracic cancers
- Various cancers requiring radiation therapy
Who it serves
- Academic Medical Centers
- Cancer Centers
- Health Systems
- Radiation Oncology Departments
Deployment & integration
On Premise · Other deployment with recorded integration context.
Recorded integration context: DICOM, HL7 FHIR, OIS (Oncology Information Systems), R&V (Record and Verify systems), TPS (Treatment Planning Systems), Various radiation therapy equipment (vendor-neutral).
Geographic context
MarketsJapan · South Korea · United States
Company sourceOfficial website
Company milestones
Platform expansion
First commercial revenue in U.S. and Japan markets; signed technology transfer agreement for core technology; selected as '2025 Best AI Radiotherapy Solution'; expanding global network; cloud-based product planned for 2026 launch
Partnerships
Recorded partners
- Kangbuk Samsung Hospital
- Samsung Seoul Hospital
- Seoul National University Hospital
- Yangsan Pusan National University Hospital
- Yonsei Cancer Hospital (Severance Hospital)
- Yonsei University Wonju College of Medicine
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
OncoPlan
AI-guided treatment planning for particle therapy optimization
Software · OtherCompany source
OncoRPT
Radiopharmaceutical therapy workflow management with personalized dosimetry
Platform · OtherCompany source
OncoStudio
AI-powered auto-contouring software that transforms hours of manual organ segmentation into minutes with clinical-grade precision
Software · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
OncoStudio (OS-01)K242994 · 510k · Feb 24, 2025
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
10x faster task completion
Compared to manual methods
75% reduction in manual tasks
Workflow automation with OncoFlow
Hours to 5 minutes
Contouring time for head and neck normal organs
1 minute average per case
Key organ contouring time
Over 90% accuracy
Expert-level contouring precision
Kangbuk Samsung Hospital
Supporting normal organ contouring in clinical settings with AI technology
Samsung Seoul Hospital
Reducing contouring time for normal organs in head and neck cancer patients to enable personalized precision radiotherapy
Reduced contouring task from several hours to just 5 minutes for head and neck cancer patients
Seoul National University Hospital
Improving quality and speed of contouring to enable more sophisticated radiation therapy and clinical research
Revolutionary improvement in quality and speed of contouring enabling personalized precision radiotherapy
Wonju Severance Christian Hospital
Automated contouring workflow for various clinical applications
Highly user-friendly and well-automated program enabling various clinical applications
Yangsan Pusan National University Hospital
Precise contouring of organs at risk and breast PTV with seamless DICOM compatibility
Excellent depiction of organs at risk and breast PTV with seamless equipment compatibility
Yonsei Cancer Hospital (Severance Hospital)
AI-based auto-segmentation for accurate separation of tumors and normal tissues
Gained competitiveness as global AI-based software through collaboration
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from OncoSoft. Co.
Recent articles published on OncoSoft. Co.'s official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Surgical AI & Robotics
Companies developing surgical technologies enhanced by AI, including robotic surgical systems, AI-powered surgical assistance and navigation tools, autonomous surgical robotics, and surgical data and analytics platforms. Covers both the performance of surgery and the analysis of surgical outcomes and OR efficiency.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.